Global Insulin Glargine Market
|Fastest Growing Market:||North America|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Global insulin glargine market is projected to witness a CAGR of 0.41% during the forecast period (2022 - 2027).
The COVID-19 pandemic has resulted in a surge in diabetic complexities, which is driving the insulin demand in the market. Type 1 diabetes can be characterized as insulin-requiring, while Type 2 diabetes can be characterized as insulin-dependent diabetes. People with diabetes have a 300% increased risk of being hospitalized compared to those without diabetes, and, thus, they incur more healthcare expenses than non-diabetic people. Patients with Type 2 diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as the administration of additional insulin or ingestion of additional carbohydrates. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy. This is driving the demand for insulin on a global scale, which is expected to drive the market studied during the forecast period.
Scope of the Report
The global insulin glargine market has been segmented by Type into Lantus, Basaglar, Toujeo, Soliqua/Suliqua, and Insulin Glargine Biosimilars. The report also covers the developments in various regions (North America, South America, Mexico, Europe, Asia-Pacific, and Middle-East and Africa), covering major countries across the globe. The report offers market size and forecasts and is represented by value (USD million) and volume (million ml).
Key Market Trends
Insulin Glargine Market Access has Widened
In 2015, Sanofi released its Toujeo in the European region as the basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. According to Sanofi data, in 2020, Toujeo posted net sales of EUR 933 million worldwide, driven by strong performances in European countries. In January 2020, Sanofi announced that the European Commission (EC) expanded the current indication for Toujeo (insulin glargine 300 units/mL) to include children and adolescents with diabetes. Toujeo is now indicated for the treatment of diabetes mellitus in adults, adolescents, and children from the age of 6 years. This is driving the market in the forecast period, whereas Basaglar was the first biosimilar to Lantus to be launched in some countries of the European Region. It offers the core protein sequence of Lantus to patients and is expected to observe an exponential increase in sales volumes during the forecast period, primarily due to its growing adoption and its lesser cost than its competitive products in the Europe Region.
To understand key trends, Download Sample Report
North-America to Grow with the Highest CAGR During the Forecast Period
Despite advancements in medical technology and health systems, patients in this region are not coping with the challenges of chronic diseases. The incidence of these diseases increased significantly over the past few years. In North America, the market share of traditional human insulin is higher due to its affordability. Novolin holds the highest market share of more than 80%, followed by Humulin and Insuman. However, these traditional brands are facing fierce competition from the local drug market. Among the drugs in the long-acting insulin segment, Lantus holds the highest market share of more than 39.6%, followed by Levemir. New generation insulin glargine, like Toujeo, Tresiba, and Basaglar, are available in only a few countries. These drugs witnessed good market penetration in the countries they were launched.
To understand geography trends, Download Sample Report
The global insulin glargine market is consolidated, with three major manufacturers (Sanofi, Novo Nordisk, and Eli Lilly) holding a global market presence. The remaining manufacturers are confined to the other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim together have an alliance in developing and commercializing Basaglar (insulin glargine) whereas Biocon collaborated with Mylan to develop Semglee (insulin glargine biosimilar). Prominent players, such as Sanofi, Novo Nordisk, and Lilly, have created a monopoly in the market through their established supply chains and branding, which has resulted in substantial market penetration. These companies work in tandem with several administrative and health agencies to deploy competitive strategies and restrict or eliminate the competition from the emerging market players.
- March 2022 - Biocon’s largest acquisition to date was in 2022 when it acquired Viatris- Biosimilars for USD 3.3 Billion. Biocon has been acquired in 2 different US states. The Company’s most targeted sectors include life science (50%) and medical products (50%).
- November 2021 - Eli Lilly and Company announced that tirzepatideelicited superior A1C and body weight reductions from baseline in adults with type 2 diabetes with increased cardiovascular risk. Data from the SURPASS-4 clinical trial, published in The Lancet, showed that all three doses of tirzepatide, 5 milligrams, 10 milligrams, and 15 milligrams, elicited statistically significant A1C bodyweight reductions compared to insulin glargine at 52 weeks.
- March 2021 - Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda is expanded for the treatment of obesity in adolescents aged 12–17 years.
Table of Contents
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Value and Volume, 2016 - 2027)
5.1.1 Insulin Glargine
220.127.116.11 Insulin Glargine Biosimilars
5.2.1 North America
18.104.22.168 United States
22.214.171.124 Rest of North America
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
5.2.3 Latin America
184.108.40.206 Rest of Latin America
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.5 Middle-East and Africa
22.214.171.124 Saudi Arabia
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2016-2027)
6.2 Type-2 Diabetes Population (2016-2027)
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk AS
7.1.2 Sanofi Aventis
7.1.3 Eli Lilly and Company
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Insulin Glargine Market market is studied from 2016 - 2027.
What is the growth rate of Global Insulin Glargine Market ?
The Global Insulin Glargine Market is growing at a CAGR of 0.41% over the next 5 years.
What is Global Insulin Glargine Market size in 2016?
The Global Insulin Glargine Market is valued at 6154 Million USD in 2016.
What is Global Insulin Glargine Market size in 2027?
The Global Insulin Glargine Market is valued at 6233 Million USD in 2027.
Which region has highest growth rate in Global Insulin Glargine Market ?
North America is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Insulin Glargine Market ?
North America holds highest share in 2021.
Who are the key players in Global Insulin Glargine Market ?
Sanofi Aventis, Novo Nordisk AS, Biocon, Eli Lilly and Company, Julphar are the major companies operating in Global Insulin Glargine Market .